REGULAXIS

REGULAXIS offers the first non-symptomatic treatment of knee osteoarthritis (OA) for which the world market was valued at USD 1.7 billion in 2016.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Romainville, France
  • Currency EUR
  • Founded September 2013
  • Employees 4
  • Incorporation Type LLC
  • Website regulaxis.com

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free